ClinicalTrials.gg
RecruitingNCT06226805RAISEUpdated Oct 13, 2026

Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)

A Phase 2 interventional study of BB-031 and Placebo in Acute Ischemic Stroke, sponsored by Basking Biosciences, Inc.. Recruiting at 25 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Basking Biosciences, Inc. · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.
Updated Oct 13, 2026Site recruiting status changedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 480 studies in Ischemic Stroke with a site in United States — 120 open to participants now, 145 under way, 13 of them phase 3. Ischemic Stroke · United States.

Planned enrollment
89th of 364
228 · median 65
Started
2024
with 30 others
Phase 2
71 of 480
8 open now
Primary completion
2027-06
later than 60 of 144 live
Registered
401st of 480
by date

Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 89th largest by planned enrollment of the 364 interventional ones that give a count, is one of 31 that started in 2024, is one of 71 in phase 2, reaches primary completion later than 60 of the 144 other live ones, and was the 401st registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

120 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 480 studies in Ischemic Stroke with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset.

Participants will be randomized to receive one dose of either the investigational drug or placebo and will be followed for 90 days. A total of 228 patients are planned in this study.

Read the detailed description

This is a two-part, randomized, placebo-controlled, double-blinded study in acute ischemic stroke patients. In Part A, up to 48 participants will be randomized in a 3:1 ratio (investigational drug: placebo) into 1 of 3 planned ascending dose groups to determine the dose levels to be studied in Part B. Two dose levels will be chosen based upon a review of all available data including safety, PK, PD and preliminary efficacy. In Part B, approximately 180 participants will be randomized to receive a single dose of two sequential dose levels of study drug or placebo.

All participants will be screened for participation after confirmed diagnosis of an anterior circulation ischemic stroke by neurovascular imaging. Enrolled participants will be followed for 90 days. Radiological outcomes will be assessed by a central blinded reviewer. A Data Safety Monitoring Committee will review safety and preliminary efficacy data throughout the study as outlined in the protocol.

03

Conditions studied

  • Acute Ischemic Stroke

Keywords

  • Stroke
  • Wake-up stroke
  • Large vessel occlusion
  • Intracranial hemorrhage
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of acute ischemic stroke
  • 18 years or older
  • Anterior circulation intra-cranial occlusion
  • NIHSS score >3
  • Onset of stroke symptoms within 24 hours of enrollment

Exclusion criteria

Exclusion Criteria:

  • Large volume ischemic stroke
  • Intracranial hemorrhage on baseline imaging or previous intracranial hemorrhage
  • Chronic intracranial occlusion
  • Weight >125kg
  • Administration of thrombolytic drug or glycoprotein IIb/IIIa inhibitors
  • Ongoing coagulopathy, history of bleeding disorder or other conditions for high-risk bleeding or active uncontrolled bleeding
  • Prior stroke within 90 days
  • Unable to undergo a CTA or MRA
  • Known severe renal disease
  • Known to any constituent of BB-031
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
228 participants (estimated)

Study arms

  • Experimental
    BB-031

    A single dose of BB-031 will be administered via IV bolus injection

    Drug: BB-031

  • Placebo comparator
    Placebo

    A single dose of matching placebo will be administered via IV bolus injection

    Drug: Placebo

Interventions

  • DrugBB-031

    Solution for injection

    Also known as: DTRI-031

  • DrugPlacebo

    0.9% sodium chloride for injection

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Symptomatic Intracranial Hemorrhage (sICH)

    Proportion of participants having a sICH

    Time frame: 24 hours

Secondary outcomes

  1. Asymptomatic intracranial hemorrhage (non-symptomatic-ICH)

    Proportion of participants having a non-symptomatic-ICH

    Time frame: 24 hours

  2. Adverse Events (AEs)

    Incidence and severity of treatment-emergent AEs

    Time frame: 24 hours

Other outcomes

  1. Mortality

    All-cause mortality

    Time frame: 30 days, 90 days

  2. Pharmacokinetic (PK) Plasma Level Assessment

    Plasma levels of study drug

    Time frame: 48 hours

  3. Pharmacokinetic (PK) Parameter

    Cmax

    Time frame: 48 hours

  4. Pharmacodynamic (PD) Assessment

    Level of free circulating von Willibrand Factor

    Time frame: 72 hours

  5. Pharmacodynamic (PD) Assessment

    von Willibrand Factor activity

    Time frame: 72 hours

  6. Recanalization

    Proportion of participants with recanalization

    Time frame: 2-9 hours

  7. Endovascular Thrombectomy (EVT)

    Proportion of participants where EVT was not performed due to clinical improvement or evidence of recanalization

    Time frame: 6 hours

  8. Stroke lesion volume

    Assessed by MRI or CT

    Time frame: 24 hours

  9. National Institutes of Health Stroke Scale (NIHSS) Score

    Change from baseline score (total score 0 to 42, with 0 representing no abnormality

    Time frame: 24 hours, 48 hours, hospital discharge and Day 90

  10. Modified Rankin Scale (mRS) Score

    Change from baseline score, where 0=no symptoms and 6=dead

    Time frame: Day 90

  11. ICU length of stay

    Duration of ICU stay

    Time frame: Up to Day 90

  12. Hospitalization length of stay

    Duration of hospitalization

    Time frame: Up to Day 90

  13. Successful reperfusion after first pass EVT

    Proportion of subjects with successful reperfusion after first pass EVT

    Time frame: 6 hours

07

Study locations

19 of 25 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jun 2027, 35 months after the start.

Of 41 industry-sponsored phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's planned 35 months is above that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2024
First posted
Jan 26, 2024
StartActual
Jul 31, 2024
Primary completionEst.
Jun 2027
CompletionEst.
Sep 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now terminated)
Show 2 sites
  • Memorial Hermann Hospital · Houston, United StatesRecruiting→Terminated
  • Monash Medical Centre · Clayton, AustraliaRecruiting→Terminated
Oct 13, 2026
Eligibility
1 exclusion criterion edited, 2 added
What changed in the criteria
Exclusion criteria
  • EditedUnable to undergo a contrast brain perfusion scan with either MRICTA or CTMRA
  • AddedKnown severe renal disease
  • AddedKnown hypersensitivity to any constituent of BB-031
Oct 13, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Memorial Hermann Hospital · Houston, United StatesContact removed (no phone or email listed)
  • Monash Medical Centre · Clayton, AustraliaContact removed (no phone or email listed)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    2 sites changed recruiting status (2 now terminated)
    Show 2 sites
    • Memorial Hermann Hospital · Houston, United StatesRecruiting→Terminated
    • Monash Medical Centre · Clayton, AustraliaRecruiting→Terminated
    Eligibility 1 exclusion criterion edited, 2 added
    What changed in the criteria
    Exclusion criteria
    • EditedUnable to undergo a contrast brain perfusion scan with either MRICTA or CTMRA
    • AddedKnown severe renal disease
    • AddedKnown hypersensitivity to any constituent of BB-031
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Memorial Hermann Hospital · Houston, United StatesContact removed (no phone or email listed)
    • Monash Medical Centre · Clayton, AustraliaContact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06226805
Lead sponsor
Basking Biosciences, Inc.
Responsible party
Sponsor
First posted
Jan 26, 2024
Start date
Jul 31, 2024
Primary completion
Jun 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Program Director
Contact
snelson@baskingbiosciences.com
9196184721
Michael D Hill, MD
principal investigator · University of Calgary
Shahid M Nimjee, MD, PhD
principal investigator · Ohio State University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion